Company news
Ainos, Inc. news in 2023
Ainos, Inc.'s news releases, calls and decks from 2023, newest first.
Ainos, Nisshinbo Micro Devices and Inabata Initiate Phase 2 of VOC Co-development Powered by AI Nose, Accelerating the Digitalization of Smell
December 25, 2023
Ainos, Inc. Announces Stock Consolidation
December 11, 2023
Ainos Announces Successful Manufacturing of VELDONA GMP Clinical Batch by Swiss Pharmaceutical
November 27, 2023
Ainos Announces Positive Data Reported from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA
November 20, 2023
Ainos Reports Third Quarter 2023 Financial Results
November 8, 2023
Ainos Signs MoU for Contract Clinical Trials to Conduct Clinical Study of Potential New Animal Drug Based on VELDONA
November 5, 2023
Ainos Announces Placement of Initial $3 Million Tranche of $10 Million Private Placement
September 24, 2023
Ainos’ VELDONA Granted Orphan Drug Designation by U.S. FDA for Potential Treatment of Oral Warts in HIV-Seropositive Patients
September 17, 2023
Ainos Commences Shipping its VELDONA Pet Cytoprotein Supplements in Taiwan
September 4, 2023
Ainos Reports Second Quarter 2023 Financial Results
August 10, 2023
Ainos Celebrates First Listing Anniversary on Nasdaq
August 9, 2023
Ainos Completes VELDONA Pet Line-Up by Launching New VELDONA Pet Shiny and Slim in Push Towards $20M Revenue Target
June 13, 2023
Ainos Launches New VELDONA Pet Lohas and Soothing Health Supplements, Catalyzing Its Drive to $20M Sales Target
June 6, 2023
Ainos Launches VELDONA Pet Cytoprotein Health Supplement Targeting $20M in Sales
May 29, 2023
Ainos Appoints Amanda Sung as New Chief Financial Officer
May 16, 2023
Ainos Reports First Quarter 2023 Financial Results
May 11, 2023
Ainos Reports Fourth Quarter and Full Year 2022 Financial Results
March 30, 2023
Ainos Signs Agreement Establishing Topmed as Exclusive Distributor of VELDONA Animal Health Supplements in Taiwan
March 20, 2023
Ainos and Merdury Sign MoU to Explore Phase 3 Study of VELDONA Drug Candidate for Treatment of Oral Warts in HIV-Seropositive Patients
March 13, 2023
Ainos Announces US$3 Million Convertible Notes Private Placement
March 12, 2023
Ainos and Tah-An Sign MoU to Explore Manufacture of VELDONA Animal Investigational New Drug
January 22, 2023
Ainos Issues 2023 Shareholder Letter
January 16, 2023